MedTrace Logo

A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B

NCT06884085 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-12-01

No results posted yet for this study

Summary

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-227 in healthy subjects.

Conditions

  • Primary Hypertension

Interventions

DRUG

Co-administration of AD-227A and AD-227B

Co-administration of AD-227A 1Tab. and AD-227B 1Tab., Per Oral

DRUG

Administration of AD-227

Administration of AD-227 1Tab., Per Oral

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-12
Primary Completion
2025-08-13
Completion
2025-08-13

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06884085 on ClinicalTrials.gov